Search

Md. Shamim Ahasan and colleagues at James Cook University in Queensland, Australia have published a study comparing phage therapy to antibiotics in treating gut dysbiosis in endangered green turtles. They found that phages (isolated from se

BiomX, a phage therapy biotech company, just announced that it's licensed new bacterial targets for commercialization of phage therapies for Primary Sclerosing Cholangitis (PSC; a rare, progressive liver disease). The targets: strains of Kl

An interesting reflection by Prof. Marc Bonten of UMC Utrecht on the current impasse in the Netherlands when it comes to the need for phage clinical trials, and on UMCU's recent discussions with national health authorities on the matter.

Boston, MA PhagePro is looking for a Principal Scientist to carry forth our research for our phage-based cholera intervention as we scale-up our studies in preparation for clinical trials. We are a flat and dynamic organization, and the Pri

Dr. Lorenzo Corsini, Vienna, Austria Do you want to be part of pioneering a high-profile antibiotics alternative and lead the research into breakthrough phage applications in areas of high medical need – together with a highly talented team

Dr. Lorenzo Corsini, Vienna, Austria Do you want to be part of developing a high-profile antibiotics alternative and help drive the research into new phage-based pharmaceuticals – together with an experienced and motivated team and a networ

This NPR article discusses Locus Biosciences' upcoming E. coli urinary tract infection phage therapy trial and interviews one of the trial volunteers—Alfonso Evans, a US Army veteran who was paralyzed by a spinal cord injury and thus suffer

Dr. Lorenzo Corsini, Vienna, Austria Do you want to be part of developing a high-profile antibiotics alternative and help drive the research into new phage-based pharmaceuticals – together with an experienced and motivated team and a networ

Dr. Lorenzo Corsini, Vienna, Austria Do you want to be part of pioneering a high-profile antibiotics alternative and lead the research into breakthrough phage applications in areas of high medical need – together with a highly talented team

A 13-month old infant was successfully treated with phage therapy (English article | Dutch article) post-liver transplant at the Saint-Luc University Hospital in Brussels. Phages were obtained from the Queen Astrid Military Hospital—read mo

The business combination transaction between AmpliPhi and C3J, two phage therapy biotech companies, is expected to close today. The new name of the combined company will be Armata Pharmaceuticals, Inc., and shares will be expected to start

How do we translate phage-based applications into clinically- and commercially-viable therapeutics? Join us Sept. 25-26, 2019 in Brussels, Belgium at Kisaco Research's Phage Futures Europe conference! The new agenda is now up, registration

How do we translate phage-based applications into clinically- and commercially-viable therapeutics? Join us Sept. 25-26, 2019 in Brussels, Belgium at Kisaco Research's Phage Futures Europe conference! The new agenda is now up, registration

Phage Futures 2019 is next week! Even if you're not able to make it, we'll be posting tweets (#PhageFutures2019) and keeping you up to date on which speaker is speaking, what people's reactions are, and who's up next. Check out our Phage Fu

Dr. Sebastian Leptihn The Leptihn Group offers a Postdoctoral Fellowship: The project involves viruses of microbes (bacteriophages) with aspects on both function and structure of phage proteins, as well as phage therapy. Experience in imagi

The business combination transaction between AmpliPhi and C3J, two phage therapy biotech companies, is expected to close today. The new name of the combined company will be Armata Pharmaceuticals, Inc., and shares will be expected to start

Dr. Sebastian Leptihn The Leptihn Group offers a Postdoctoral Fellowship: The project involves viruses of microbes (bacteriophages) with aspects on both function and structure of phage proteins, as well as phage therapy. Experience in imagi

Andrei Bolocan and colleagues from APC Microbiome, the University College Cork and the Teagasc Food Research Centre in Ireland have published a new review evaluating the prospects of E. faecalis phage therapy. They've categorized phages wit

A new preprint by Dr. Aleksandra Petrovic Fabijan and colleagues at the Westmead Institute for Medical Research in Sydney, Australia and AmpliPhi Biosciences provides much-awaited data from their IV phage therapy treatment of 13 patients wi

A new preprint by Dr. Aleksandra Petrovic Fabijan and colleagues at the Westmead Institute for Medical Research in Sydney, Australia and AmpliPhi Biosciences provides much-awaited data from their IV phage therapy treatment of 13 patients wi